AerovectRx Corp. to Present Latest Drug Delivery Innovations at Medtech Insight's ``Investment In Innovation'' West Conference.

IRVINE, Calif. -- AerovectRx Corporation, developers of new, pain-free nebulizer technology for mass-immunization and point-of care specialty drug delivery, announced that it will be presenting at Medtech Insight's "Investment In Innovation" (In3) West Conference, taking place Feb. 23-24, at the Hyatt Regency Irvine in Irvine. E[acute accent]"AerovectRx's unique, painless technology platform provides fast and easy delivery of a wide range of therapies and vaccines, providing access to multi-billion-dollar market opportunities, including influenza, idiopathic pulmonary fibrosis and diabetes," said Matthew Kim, founder and CEO of AerovectRx. "We believe that our technology is attractive to pharmaceutical companies seeking to maximize delivery of their drugs and also to physicians and patients alike seeking to remove the pain barrier of injections." E[acute accent]AerovectRx's technology centers on the proprietary AeroCell(TM) disposable drug cartridge that provides for highly efficient and effective inhaled delivery of vaccines and therapeutics and a continuing revenue stream. Additionally, the product configuration consists of a hand-held, battery-powered unit and a single-patient-use, disposable mask. The company's planned initial product will be the multi-use, mass-inoculation Aerolife(TM) system -- the first multiple-use, mass-immunization nebulizer drug delivery system. The next-generation Aerocurrent(TM) system is designed for use in the point-of-care market to deliver vaccines and therapeutics in established markets. E[acute accent]"Our unique design provides for a platform that can be leveraged across multiple markets along with a consumable accessories revenue stream in addition to the actual drug being administered. We plan to partner with pharmaceutical and biotechnology companies with established market presence and a sales and distribution infrastructure already in place. Potential customers include public health agencies for the mass-immunization Aerolife(TM) system and hospitals, doctor's offices, clinics and individuals for various applications of the Aerocurrent(TM) system," said Kim. E[acute accent]AerovectRx Corporation is an early stage company developing novel pulmonary drug delivery technology licensed from the U.S. Centers for Disease Control and Prevention (CDC). Products under development by AerovectRx are designed to deliver a wide variety of therapies and vaccines through mass immunization and personal nebulizers. Initially targeted therapeutics for the AerovectRx technology include treatments for asthma, idiopathic pulmonary fibrosis, avian flu and diabetes. For more information, visit www.aerovectrx.com. E[acute accent]Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register to attend In3 West, call Kristy Grimes of Medtech Insight at 480-985-9512, 888-202-5939 toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.